サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439250

構造的心疾患向けデバイス - 世界市場の考察、競合情勢、市場予測（2030年）

Structural Heart Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
構造的心疾患向けデバイス - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の構造的心疾患向けデバイスの市場規模は、2023年に98億1,000万米ドル、2030年までに186億7,000万米ドルに達し、2024年～2030年の予測期間にCAGRで11.33％の成長が見込まれます。構造的心疾患向けデバイスの需要は、主に構造的心臓疾患の有病率の急速な増加、低侵襲介入の人気の高まり、製品開発における研究開発活動の増加、新製品や先進の製品の承認、さまざまな償還および保険プログラムへの構造的心疾患向けデバイスの組み込みによって後押しされています。

心臓構造デバイスの市場力学

2020年にLancetで発表された「Global, regional, and national burden of congenital heart disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017」によると、先天性心疾患は2017年に世界中で26万1,247人の死亡を引き起こし、そのうち18万624人が乳幼児でした。CHDに関連する死亡率は、社会人口統計学的指標の増加により年々減少しているにもかかわらず、先天性疾患の有病率は年々増加しており、2017年に1,199万8,283人が先天性疾患を抱えて生活しています。

British Heart Foundationのファクトシートによると、2022年、英国では出生児の約50人に1人が心臓異常と診断され、これは英国では毎日平均約13人の赤ちゃんが心臓異常と診断されることになり、後年より多くの診断が下されることになります。推計によると、英国では人口の1～2％がCHDに罹患している可能性があります。

2020年にGraveらによってJournal of the American Heart Associationで発表された「Epidemiological Features of Aortic Stenosis in a French Nationwide Study: 10-Year Trends and New Challenges」によると、大動脈弁狭窄症（AS）は欧州でもっとも一般的な心臓弁膜症であり、米国では2番目に多い疾患です。大動脈弁狭窄症の有病率は年齢とともに指数関数的に増加し、米国では65歳未満で人口の0.2％、75歳以上で2.8％と推定されています。

さらに、構造的心疾患の治療において、経カテーテル修復や置換術のような低侵襲手技の人気が高まっていることも、構造的心疾患向けデバイス市場の成長にとって重大な情勢をもたらしています。

しかし、製品リコール件数と製品の承認に向けた厳格な規制基準が、予測期間に構造的心疾患向けデバイス市場の成長を抑制する可能性があります。

構造的心疾患向けデバイス市場のセグメント分析

構造的心疾患向けデバイス市場の製品セグメントでは、置換術用デバイスに比べて修復術用デバイスのカテゴリが大きな市場シェアを占めると予測されています。これは、外科医が第一選択として置換術よりも修復術を好むことに起因しています。これは、心臓の構造的欠陥の治療において、修復術が心筋の強度や機能を維持する傾向があることや、心内膜炎などの術後感染症の可能性を低減すること、置換術用デバイスと比較して予後が良好であること、血液希釈剤への依存度が比較的低いことなど、修復術に関連する複数の利点があるためです。

修復術カテゴリでは、弁修復術、特に僧帽弁修復術におけるその重要性から、弁形成デバイスが大きな市場シェアを獲得すると予測されています。弁形成術用リングは、弁本来の弁輪の形や大きさを復元するのに役立ち、将来的な弁輪の拡張を防ぎ、弁輪に機能的な支援をもたらすため、不可欠なものと考えられています。さらに、これらのデバイスは、開心手術または低侵襲アプローチの両方で治療として実施できる柔軟性を備えています。

当レポートでは、世界の構造的心疾患向けデバイス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 構造的心疾患向けデバイス市場レポートのイントロダクション

第2章 構造的心疾患向けデバイス市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第4章 構造的心疾患向けデバイス市場の主な要因の分析

  • 構造的心疾患向けデバイス市場の促進要因
    • 構造的心疾患の有病率の上昇
    • 低侵襲手術に対する需要の高まり
    • 新製品開発につながる技術の進歩
    • さまざまな償還および保険プログラムへの構造的心疾患向けデバイスの組み込み
  • 構造的心疾患向けデバイス市場の抑制要因と課題
    • 頻繁な製品の故障とリコール
    • 厳格な製品承認プロセス
  • 構造的心疾患向けデバイス市場の機会
    • 新興市場をターゲットにした製品の発売
    • 製品の安全面の向上

第5章 構造的心疾患向けデバイス市場のポーターのファイブフォース分析

第6章 構造的心疾患向けデバイス市場に対するCOVID-19の影響の分析

第7章 構造的心疾患向けデバイス市場レイアウト

  • 製品タイプ別
    • 修復術用デバイス
    • 置換術用デバイス
  • 用途別
    • 心房中隔欠損症
    • 大動脈弁狭窄症
    • 卵円孔開存
    • 心室中隔欠損症
    • 僧帽弁閉鎖不全症
    • その他
  • エンドユーザー別
    • 病院
    • 外来手術センター
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 構造的心疾患向けデバイス市場：世界の企業シェア分析 - 主要3～5社

第9章 構造的心疾患向けデバイス市場の企業と製品のプロファイル

  • Medtronic
  • Boston Scientific Corporation
  • Braile Biomedica
  • Edwards Life Sciences Corporation
  • Valcare Medical
  • W. L. Gore & Associates Inc
  • Abbott
  • XELTIS BV
  • JenaValve Technology, Inc
  • Lepu Medical Technology (Beijing) Co. Ltd
  • Livanova plc
  • Comed BV
  • TORAY INDUSTRIES INC
  • Occlutech International AB
  • Microport Scientific Corporation

第10章 プロジェクトのアプローチ

  • 二次資料
  • 一次資料
  • データの三角測量
  • 主な専門家の意見

第11章 KOLの見解

第12章 DelveInsightのサービス内容

第13章 免責事項

第14章 DelveInsightについて

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Structural Heart Devices Market
  • Table 3: Structural Heart Devices Market in Global (2021-2030)
  • Table 4: Structural Heart Devices Market in Global by Product Type (2021-2030)
  • Table 5: Structural Heart Devices Market in Global by Application (2021-2030)
  • Table 6: Structural Heart Devices Market in Global by End User (2021-2030)
  • Table 7: Structural Heart Devices Market in Global by Geography (2021-2030)
  • Table 8: Structural Heart Devices Market in North America (2021-2030)
  • Table 9: Structural Heart Devices Market in North America by Product Type (2021-2030)
  • Table 10: Structural Heart Devices Market in North America by Application (2021-2030)
  • Table 11: Structural Heart Devices Market in North America by End User (2021-2030)
  • Table 12: Structural Heart Devices Market in North America by Country (2021-2030)
  • Table 13: Structural Heart Devices Market in the US (2021-2030)
  • Table 14: Structural Heart Devices Market in Canada (2021-2030)
  • Table 15: Structural Heart Devices Market in Mexico (2021-2030)
  • Table 16: Structural Heart Devices Market in Europe (2021-2030)
  • Table 17: Structural Heart Devices Market in Europe by Product Type (2021-2030)
  • Table 18: Structural Heart Devices Market in Europe by Application (2021-2030)
  • Table 19: Structural Heart Devices Market in Europe by End User (2021-2030)
  • Table 20: Structural Heart Devices Market in Europe by Country (2021-2030)
  • Table 21: Structural Heart Devices Market in France (2021-2030)
  • Table 22: Structural Heart Devices Market in Germany (2021-2030)
  • Table 23: Structural Heart Devices Market in the United Kingdom (2021-2030)
  • Table 24: Structural Heart Devices Market in Italy (2021-2030)
  • Table 25: Structural Heart Devices Market in Spain (2021-2030)
  • Table 26: Structural Heart Devices Market in Russia (2021-2030)
  • Table 27: Structural Heart Devices Market in Rest of Europe (2021-2030)
  • Table 28: Structural Heart Devices Market in APAC (2021-2030)
  • Table 29: Structural Heart Devices Market in APAC by Product Type (2021-2030)
  • Table 30: Structural Heart Devices Market in APAC by Application (2021-2030)
  • Table 31: Structural Heart Devices Market in APAC by End User (2021-2030)
  • Table 32: Structural Heart Devices Market in APAC by Country (2021-2030)
  • Table 33: Structural Heart Devices Market in China (2021-2030)
  • Table 34: Structural Heart Devices Market in Japan (2021-2030)
  • Table 35: Structural Heart Devices Market in India (2021-2030)
  • Table 36: Structural Heart Devices Market in Australia (2021-2030)
  • Table 37: Structural Heart Devices Market in South Korea (2021-2030)
  • Table 38: Structural Heart Devices Market in Rest of APAC (2021-2030)
  • Table 39: Structural Heart Devices Market in Rest of World (2021-2030)
  • Table 40: Structural Heart Devices Market in RoW by Product Type (2021-2030)
  • Table 41: Structural Heart Devices Market in RoW by Application (2021-2030)
  • Table 42: Structural Heart Devices Market in RoW by End User (2021-2030)
  • Table 43: Structural Heart Devices Market in RoW by Region (2021-2030)
  • Table 44: Structural Heart Devices Market in Middle East (2021-2030)
  • Table 45: Structural Heart Devices Market in Africa (2021-2030)
  • Table 46: Structural Heart Devices Market in South America (2021-2030)

List of Figures

Figures 1: Competitive Analysis

Figures 2: COVID-19 Impact Analysis on Structural Heart Devices Market

Figures 3: Structural Heart Devices Market in Global (2021-2030)

Figures 4: Structural Heart Devices Market in Global by Product Type (2021-2030)

Figures 5: Structural Heart Devices Market in Global by Application (2021-2030)

Figures 6: Structural Heart Devices Market in Global by End User (2021-2030)

Figures 7: Structural Heart Devices Market in Global by Geography (2021-2030)

Figures 8: Structural Heart Devices Market in North America (2021-2030)

Figures 9: Structural Heart Devices Market in North America by Product Type (2021-2030)

Figures 10: Structural Heart Devices Market in North America by Application (2021-2030)

Figures 11: Structural Heart Devices Market in North America by End User (2021-2030)

Figures 12: Structural Heart Devices Market in North America by Country (2021-2030)

Figures 13: Structural Heart Devices Market in the US (2021-2030)

Figures 14: Structural Heart Devices Market in Canada (2021-2030)

Figures 15: Structural Heart Devices Market in Mexico (2021-2030)

Figures 16: Structural Heart Devices Market in Europe (2021-2030)

Figures 17: Structural Heart Devices Market in Europe by Product Type (2021-2030)

Figures 18: Structural Heart Devices Market in Europe by Application (2021-2030)

Figures 19: Structural Heart Devices Market in Europe by End User (2021-2030)

Figures 20: Structural Heart Devices Market in Europe by Country (2021-2030)

Figures 21: Structural Heart Devices Market in France (2021-2030)

Figures 22: Structural Heart Devices Market in Germany (2021-2030)

Figures 23: Structural Heart Devices Market in the United Kingdom (2021-2030)

Figures 24: Structural Heart Devices Market in Italy (2021-2030)

Figures 25: Structural Heart Devices Market in Spain (2021-2030)

Figures 26: Structural Heart Devices Market in Russia (2021-2030)

Figures 27: Structural Heart Devices Market in Rest of Europe (2021-2030)

Figures 28: Structural Heart Devices Market in APAC (2021-2030)

Figures 29: Structural Heart Devices Market in APAC by Product Type (2021-2030)

Figures 30: Structural Heart Devices Market in APAC by Application (2021-2030)

Figures 31: Structural Heart Devices Market in APAC by End User (2021-2030)

Figures 32: Structural Heart Devices Market in APAC by Country (2021-2030)

Figures 33: Structural Heart Devices Market in China (2021-2030)

Figures 34: Structural Heart Devices Market in Japan (2021-2030)

Figures 35: Structural Heart Devices Market in India (2021-2030)

Figures 36: Structural Heart Devices Market in Australia (2021-2030)

Figures 37: Structural Heart Devices Market in South Korea (2021-2030)

Figures 38: Structural Heart Devices Market in Rest of APAC (2021-2030)

Figures 39: Structural Heart Devices Market in Rest of World (2021-2030)

Figures 40: Structural Heart Devices Market in RoW by Product Type (2021-2030)

Figures 41: Structural Heart Devices Market in RoW by Application (2021-2030)

Figures 42: Structural Heart Devices Market in RoW by End User (2021-2030)

Figures 43: Structural Heart Devices Market in RoW by Region (2021-2030)

Figures 44: Structural Heart Devices Market in Middle East (2021-2030)

Figures 45: Structural Heart Devices Market in Africa (2021-2030)

Figures 46: Structural Heart Devices Market in South America (2021-2030)

Figures 47: Market Drivers

Figures 48: Market Barriers

Figures 49: Marker Opportunities

Figures 50: PORTER'S Five Force Analysis

目次
Product Code: DIMDCL0037

Structural Heart Devices Market By Product Type (Repair Devices [Occluders, Annuloplasty Devices, Valvuloplasty Devices, Others] And Replacement Devices [Mechanical Heart Valves And Tissue Heart Valves]), By Application (Atrial Spetal Defect, Aortic Valve Stenosis, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Regurgitation, And Others) And By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of structural heart diseases and the development of new products.

Global Structural Heart Devices Market was valued at USD 9.81 billion in 2023, growing at a CAGR of 11.33% during the forecast period from 2024 to 2030 to reach USD 18.67 billion by 2030. The demand for structural heart devices is primarily being boosted by the rapid growth in the prevalence of structural heart diseases, growing popularity of minimally invasive interventions, increase in the research and development activities in product development, the approval of new and advanced products, and the inclusion of structural heart devices in various reimbursement & insurance programs.

Structural Heart Devices Market Dynamics:

As per the Global Burden of Diseases Study published in the Lancet journal in 2020, titled "Global, regional, and national burden of congenital heart disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017", congenital heart disease caused 261,247 deaths across the globe in 2017, of which 180,624 were infants. Even though the mortality rates associated with CHD have decreased over the years due to increasing socio-demographic index, the prevalence of congenital diseases have witnessed an increase over the years with 11,998,283 people living with it in 2017.

According to the factsheet by the British Heart Foundation, 2022, about one in 50 births are diagnosed with heart defects in the UK, which averages to about 13 babies each day in the UK with more diagnoses later in life. Estimates suggest that in total as many as 1-2 per cent of the population in the country may be affected with CHD.

As per the study published in the Journal of the American Heart Association by Grave et al in 2020 titled "Epidemiological Features of Aortic Stenosis in a French Nationwide Study: 10-Year Trends and New Challenges", aortic stenosis (AS) is the most common form of valvular heart disease in Europe, and the second most common indication in the United States. The prevalence of aortic stenosis is estimated to increase exponentially with age and has been estimated at 0.2% of the US population before the age of 65 years and 2.8% after the age of 75 years.

Moreover, the rising popularity of minimally invasive procedures such as transcatheter repair and replacement techniques in treating structural heart diseases, have further provided great landscape for the structural heart devices market growth.

However, the number of product recalls and rigid regulatory norms for product approval may restrain the growth of the structural heart devices market during the forecast period.

Structural Heart Devices Market Segment Analysis:

Structural Heart Devices market by Product Type (Repair Devices [Occluders, Annuloplasty Devices, Valvuloplasty Devices, Others] and Replacement Devices [Mechanical Heart Valves And Tissue Heart Valves]), Structural Heart Devices market by Application (Atrial Septal Defect, Aortic Valve Stenosis, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Regurgitation, And Others) Structural Heart Devices market by End User (Hospitals, Ambulatory Surgical Centers, And Others), and Structural Heart Devices market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In product segment of the structural heart devices market, the repair devices category is expected to account for the larger market share compared to the replacement devices. This can be attributed to the preference of surgeons to repair procedures over replacement ones as the first choice. These is due to the several benefits associated with the repair procedures in treating structural heart defects such as repairing strategies tend to preserve the strength, and function of the heart muscle, reduces the chances of post-surgery infections such as endocarditis, offers better prognosis compared to replacement devices, and comparatively less dependency on blood-thinners.

In the repair category, annuloplasty devices are expected to amass significant market share due to their significant importance in valve repair, specifically the mitral valve. An annuloplasty ring is considered essential as it helps in restoring the shape and the size of the native annulus of the valve, it prevents future dilation of the annulus, and offers functional support to the annulus. Furthermore, these devices offer the flexibility to be administered as a treatment both via an open heart surgery or minimally invasive approach.

In October 2020, Genesee BioMedical Inc received the FDA approval for their TruForm Sievers Annuloplasty Ring, Model TRH for the treatment of the correction of mitral valvular insufficiency where the lesions are not so severe as to require total valve replacement.

However, the rising popularity of minimally invasive interventions such as transcatheter-based approaches for valve repair such as Edwards Cardioband Mitral Reconstruction System, MitraClip and Carillon Mitral Contour System are expected to witness a faster growth in demand in the forecast period.

North America is expected to dominate the Overall Strucutral Heart Devices Market:

Among all the regions, North America is expected to amass the largest share in the structural heart devices market. The growing prevalence of structural heart disease, better healthcare facilities coupled with the presence of major market players as well as supportive reimbursement programs in the region are predicted to be the major influencing factors in driving the overall growth of the structural heart devices market over the forecast period.

In North America, the US is expected to account for the largest share of the North American Structural Heart Devices market. This can be attributed to the increasing cases of structural heart diseases. According to the Centers for Disease Control and Prevention (CDC) data (2023), congenital heart diseases affect approximately 40,000 births per year in the country. It has been estimated that about one in 4 babies suffer from a critical form of CHD. The commonest type of heart defect is the ventricular septal defect.

As per the data provided by the CDC (2023), near about 2.5% of the US population suffers from valvular heart disease and it is more commonly observed in the older population.

Aortic stenosis is one of the commonest and serious valve disease problems and is one of the type of valvular heart diseases. The aortic valve opening becomes narrow in this indication which results in the restricted blood flow from the left ventricle to the aorta. As per the factsheet provided by the American Heart Association (2023), about 20% of the people in the United States over the age of 65 suffer from aortic stenosis.

Moreover, the large presence of key market players namely Abbott, Edwards Lifesciences Corporation, Livanova plc in the country as well as the launch of new products in the country also provide favorable conditions for the growth of the structural heart devices market.

In September 2020, the US Food and Drug Administration expanded the product approval for the The SAPIEN 3 and SAPIEN 3 Ultra THV System by Edwards Lifesciences Corporation to include the replacement of a failing (narrowed, leaky, or both) use previously implanted transcatheter aortic valve. The device has been previously approved to be used in the treatment of aortic stenosis as well as a replacement for the replacement of a failing (narrowed, leaky, or both) previously implanted surgical artificial aortic or mitral heart valve in patients who are too high risk for open-heart surgery. Such frequent revisions of the device applications and safety assessment by the country's regulatory authorities also play a key role in instilling faith in device manufacturers and end users.

Therefore, the market for structural heart devices in the United States and North America is predicted to witness significant growth in the forecast period.

Structural Heart Devices Market Key Players:

Some of the key market players operating in the structural heart devices market includes Medtronic, Boston Scientific Corporation, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, Valcare Medical, W. L. Gore & Associates, Inc, Abbott, Cardiovascular Systems, Inc., XELTIS BV, JenaValve Technology, Inc, Biomerics, Lepu Medical Technology (Beijing) Co. Ltd, Livanova plc, Comed B.V., TORAY INDUSTRIES INC, Occlutech International AB, Microport Scientific Corporation and others.

Recent Developmental Activities in Structural Heart Devices Market:

In August 2022, Medtronic received the 510k clearance from the US Food and Drug Administration for their new-generation, self-expanding transcatheter aortic valve replacement (TAVR) system- Evolut FX TAVR system. This device is aimed at treating patients with symptomatic severe aortic stenosis while maintaining the feautres offered by their Evolut platform such as hemodynamics and durability.

In August 2022, Occlutech Holding AG was granted an Investigational Device Exemption (IDE) by the US FDA for their Flex II PFO Occluder. This IDE would allow the company to conduct a clinical study to gather safety and efficacy data for their device to support their premarket approval in order to access the US markets.

In March 2022, Medtronic received the 510k approval by the US FDA for their Harmony Transcatheter Pulmonary Valve System. This system is the first-ever non-surgical valve replacement device in the world for the treatment of certain types of congenital heart disease in both adult and pediatric populations.

Key Takeaways from the Structural Heart Devices Market Report Study

Market size analysis for current structural heart devices market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the structural heart devices market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global structural heart devices market.

Various opportunities available for the other competitor in the structural heart devices market space.

What are the top performing segments in 2023? How these segments will perform in 2030?

Which is the top-performing regions and countries in the current structural heart devices market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for structural heart devices market growth in the coming future?

Target Audience who can be benefited from this Structural Heart Devices Market Report Study

Structural Heart Devices products providers

Research organizations and consulting companies

Structural Heart Devices-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in structural heart devices

Various End-users who want to know more about the structural heart devices market and latest technological developments in the structural heart devices market.

Frequently Asked Questions for Structural Heart Devices Market:

1. What is are Structural Heart Devices?

Structural heart devices are various types of devices that are used in the treatment of structural heart defects. Depending upon the degree of the defect, different types of structural heart devices can be employed either in the repair of the defect or replacement, such as replacement of a heart valve.

2. What is the market for Global Structural Heart Devices?

Global Structural Heart Devices Market was valued at USD 8.82 billion in 2023, growing at a CAGR of 11.33% during the forecast period from 2024 to 2030 to reach USD 18.67 billion by 2030.

3. What are the drivers for Global Structural Heart Devices Market?

The major factors boosting the demand for Structural Heart Devices in the market the rising prevalence of structural heart diseases, increasing popularity of minimally invasive interventions, and favourable reimbursement programs related to these procedures.

4. What are the key players operating in Global Structural Heart Devices?

Some of the important market players operating in the the structural heart devices market includes Medtronic, Boston Scientific Corporation, Braile Biomedica, JOTEC GmbH, Edwards Life Sciences Corporation, Valcare Medical, W. L. Gore & Associates, Inc, Abbott, Cardiovascular Systems, Inc., XELTIS BV, JenaValve Technology, Inc, Biomerics, Lepu Medical Technology (Beijing) Co. Ltd, Livanova plc, Comed B.V., TORAY INDUSTRIES INC, Occlutech International AB, Microport Scientific Corporation and others.

5. What region has the highest share in Structural Heart Devices market?

North America is projected to dominate the structural heart devices market in terms of revenue in the during the forecast period. This can be related to the high number of cases of structural heart diseases, better healthcare system, and presence of major market players in the region, primarily in the US.

Table of Contents

1.Structural Heart Devices Market Report Introduction

2.Structural Heart Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
    • 3.2.1. Germany
    • 3.2.2. France
    • 3.2.3. Italy
    • 3.2.4. Spain
    • 3.2.5. U.K.
  • 3.3. Japan

4. Structural Heart Devices Market Key Factors Analysis

  • 4.1. Structural Heart Devices Market Drivers
    • 4.1.1. Rising Prevalence of Structural Heart Diseases
    • 4.1.2. Growing demand for Minimally-Invasive Procedures
    • 4.1.3. Technological Advancements Leading to New Product Development
    • 4.1.4. Inclusion of Structural Heart Devices In Various Reimbursement & Insurance Programs
  • 4.2. Structural Heart Devices Market Restraints and Challenges
    • 4.2.1. Frequent Product Failures and Recalls
    • 4.2.2. Stringent Product Approval Process
  • 4.3. Structural Heart Devices Market Opportunities
    • 4.3.1. Targeting Emerging Markets for Product Launches
    • 4.3.2. Product Improvement in Terms of Safety

5. Structural Heart Devices Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Structural Heart Devices Market

7. Structural Heart Devices Market Layout

  • 7.1. By Product Type
    • 7.1.1. Repair Devices
      • 7.1.1.1. Occluders
      • 7.1.1.2. Annuloplasty Devices
      • 7.1.1.3. Valvuloplasty Devices
      • 7.1.1.4. Others
    • 7.1.2. Replacement Devices
      • 7.1.2.1. Mechanical Valves
      • 7.1.2.2. Tissue Valves
  • 7.2. By Application
    • 7.2.1. Atrial Septal Defects
    • 7.2.2. Aortic Valve Stenosis
    • 7.2.3. Patent Foramen Ovale
    • 7.2.4. Ventricular Septal Defects
    • 7.2.5. Mitral Valve Regurgitation
    • 7.2.6. Others
  • 7.3. By End User
    • 7.3.1. Hospitals
    • 7.3.2. Ambulatory Surgical Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. North America Structural Heart Devices Market, by Product Type
      • 7.4.1.2. North America Structural Heart Devices Market, by Application
      • 7.4.1.2. North America Structural Heart Devices Market, by End User
      • 7.4.1.4. North America Structural Heart Devices Market, by Country
      • 7.4.1.1.1. United States
      • 7.4.1.1.2. Canada
      • 7.4.1.1.3. Mexico
    • 7.4.2. Europe
      • 7.4.2.1. Europe Structural Heart Devices Market, by Product Type
      • 7.4.2.2. Europe Structural Heart Devices Market, by Application
      • 7.4.2.3. Europe Structural Heart Devices Market, by End User
      • 7.4.2.4. Europe Structural Heart Devices Market, by Country
      • 7.4.2.2.1. France
      • 7.4.2.2.2. Germany
      • 7.4.2.2.3. United Kingdom
      • 7.4.2.2.4. Italy
      • 7.4.2.2.5. Spain
      • 7.4.2.2.6. Russia
      • 7.4.2.2.7. Rest of Europe
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. Asia-Pacific Structural Heart Devices Market, by Product Type
      • 7.4.3.2. Asia-Pacific Structural Heart Devices Market, by Application
      • 7.4.3.3. Asia-Pacific Structural Heart Devices Market, by End User
      • 7.4.3.4. Asia-Pacific Structural Heart Devices Market, by Country
      • 7.4.3.4.1. China
      • 7.4.3.4.2. Japan
      • 7.4.3.4.3. India
      • 7.4.3.4.4. Australia
      • 7.4.3.4.5. South Korea
      • 7.4.3.4.6. Rest of Asia Pacific
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. RoW Structural Heart Devices Market, by Product Type
      • 7.4.4.2. RoW Structural Heart Devices Market, by Application
      • 7.4.4.3. RoW Structural Heart Devices Market, by End User
      • 7.4.4.4. RoW Structural Heart Devices Market, by Country
      • 7.4.4.3.1. Middle East
      • 7.4.4.3.2. Africa
      • 7.4.4.3.3. South America

8. Structural Heart Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Structural Heart Devices Market Company and Product Profiles

  • 9.1. Medtronic
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Boston Scientific Corporation
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Braile Biomedica
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Edwards Life Sciences Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Valcare Medical
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. W. L. Gore & Associates Inc
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Abbott
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. XELTIS BV
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. JenaValve Technology, Inc
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Lepu Medical Technology (Beijing) Co. Ltd
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Livanova plc
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Comed BV
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. TORAY INDUSTRIES INC
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Occlutech International AB
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Microport Scientific Corporation
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy

10. Project Approach

  • 10.1. Secondary Sources
  • 10.2. Primary Sources
  • 10.3. Data Triangulation
  • 10.4. Key Expert Opinions

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight